SLC5A2 and heart failure: Previous studies have demonstrated that empagliflozin attenuates cardiac dysfunction by reducing NLRP3 inflammasome activation in heart failure models, and that SGLT2 inhibitors counteract NLRP3 activation via the immunomodulatory metabolite itaconate in ischemia-reperfusion injury (IRI) models.